Trial Profile
A Phase I Study to Investigate the Safety and Clinical Activity of Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 mAb in Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Idelalisib (Primary) ; Bendamustine; Bortezomib; Chlorambucil; Everolimus; Fludarabine; Lenalidomide; Ofatumumab; Rituximab
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia; Mantle-cell lymphoma
- Focus Adverse reactions
- Sponsors Gilead Sciences
- 07 Jun 2016 Results of post-hoc analysis of this and other trials (n=1073) presented at the 52nd Annual Meeting of the American Society of Clinical Oncology.
- 08 Dec 2015 Results of post-hoc analysis (n=494) of this and other three trial (see profile 59751, 214177 and 35836) were presented at the 57th Annual Meeting and Exposition of the American Society of Hematology
- 02 Jun 2015 Long-term results in patients with chronic lymphocytic leukaemia presented at the 51st Annual Meeting of the American Society of Clinical Oncology.